Globus Medical Inc. Class A Common Stock vs Mercadolibre Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Mercadolibre Inc trades at $1,823.88 (market cap $93.24B). The key difference: Mercadolibre Inc is far larger — about 9.1× Globus Medical Inc. Class A Common Stock's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Mercadolibre Inc for 118 Days on average.
| GMED | MELI | |
|---|---|---|
Market Cap | $10.25B | $93.24B |
Volume | 1,059,528 | 380,071 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $2.36K |
52-Week Low | $58.33 | $1.55K |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $9.76B | $100.88B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
MercadoLibre (MELI) trades at $1,876.04, down 0.87% on the day, with strong technical bullish signals from moving averages. The company demonstrates robust revenue growth, reaching $28.89 billion in 2025, though net income margin declined to 6.91%. Recent news highlights expansion in Brazil with one-hour delivery services and growing fintech credit portfolio, while analyst consensus remains strongly bullish with a $2,160 price target.
MELI presents a compelling growth story in Latin American e-commerce and fintech, supported by expanding market share and ecosystem integration. Key risks include macroeconomic pressures in Argentina and margin compression despite revenue growth. With 73% analyst buy ratings and institutional accumulation, the stock offers upside potential but requires monitoring of profitability trends and regional economic stability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →